Doctors Note Logo

Published on: 9/24/2026

What are the side effects of Genglycos?

Side effects reported with Genglycos can range from mild and temporary to serious, and may include digestive upset such as nausea, stomach discomfort, or changes in bowel habits, along with headache, dizziness, or skin reactions in some people. Less common but more concerning reactions can involve allergic symptoms, unusual fatigue, or changes in blood sugar levels, which may require prompt medical attention. Your dose, other medications, age, and underlying conditions all influence which effects you may experience and how long they last, so there are several important factors to consider before assuming a symptom is harmless. See below for the complete answer, including which reactions typically fade on their own and which ones warrant contacting a clinician right away.

If you are noticing symptoms and are unsure whether they are a normal medication effect or a sign of something else, a free, instant, online symptom check can help you organize what you are feeling, see possible explanations, and understand whether self-care, a pharmacist conversation, or urgent care is the smartest next step.

Last reviewed for medical accuracy: 09/24/2026

answer background

Explanation

Genglycos is an aminoglycoside-class antibiotic often used to treat serious Gram-negative infections. Like all powerful medications, it can cause side effects. Below is a balanced overview of what to watch for—presented in clear, everyday language. If you ever feel something is wrong, consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker and always speak to a doctor about anything that could be life-threatening or serious.

How Genglycos Works

Genglycos binds to bacterial ribosomes, disrupting protein synthesis and killing susceptible bacteria. It’s usually reserved for hospital settings or tough infections because of its potency and potential toxicity.

Common genglycos side effects

Most people tolerate Genglycos fairly well in the short term. These side effects often show up in 1–10% of patients:

  • Kidney changes
    • Mild rise in blood urea nitrogen (BUN) or creatinine
    • Often reversible once treatment stops
  • Gastrointestinal discomfort
    • Nausea or vomiting
    • Occasional diarrhea
  • Injection-site reactions (if given intravenously or intramuscularly)
    • Local redness, pain or swelling
  • Headache or mild dizziness
  • Mild rash or itching

In many cases, basic monitoring (blood tests and vital signs) helps catch and manage these quickly.

Serious genglycos side effects

Though less common, these adverse effects require immediate attention:

  • Nephrotoxicity (kidney damage)
    • Signs: sharp rise in creatinine, reduced urine output, swelling in hands/feet
    • Risk factors: dehydration, other nephrotoxic drugs, older age
  • Ototoxicity (hearing and balance issues)
    • Early warning: tinnitus (ringing in ears), hearing loss, vertigo
    • Can be permanent if not caught early
  • Neuromuscular blockade
    • Rare but severe: muscle weakness, breathing difficulties
    • More likely if you’re also on muscle-relaxing agents
  • Severe allergic reactions (anaphylaxis)
    • Symptoms: rash, hives, facial swelling, difficulty breathing
    • Requires emergency care
  • Blood disorders
    • Low platelets (thrombocytopenia), low white cells (leukopenia)
    • May increase bleeding or infection risk

Who’s at higher risk?

Certain factors can raise your chances of side effects:

  • Preexisting kidney disease or dehydration
  • Advanced age (over 65)
  • Concurrent use of other nephrotoxic or ototoxic drugs (e.g., vancomycin, loop diuretics)
  • High doses or prolonged therapy (beyond 7–10 days)
  • Underlying neuromuscular disorders (e.g., myasthenia gravis)

If you fall into any of these categories, your doctor will likely adjust the dose and increase monitoring.

What to watch for—and when to call your doctor

Stay alert for any new or worsening symptoms:

  1. Kidney warning signs

    • Dark, low-volume urine
    • Swelling in ankles or around the eyes
    • Unexplained fatigue or nausea
  2. Ear and balance warning signs

    • Ringing or buzzing in ears
    • Hearing voices or sounds that aren’t there
    • Feeling unsteady on your feet
  3. Breathing or muscle trouble

    • Shortness of breath out of proportion to activity
    • Drooping eyelids or overall muscle weakness
  4. Allergic reaction

    • Hives or widespread rash
    • Sudden swelling of face, lips or throat
    • Wheezing or chest tightness

If you notice any of these, seek medical help right away.

Tips to lower your risk

You and your care team can work together to minimize side effects:

  • Stay well hydrated—unless your doctor has given fluid restrictions
  • Get routine bloodwork (kidney function, blood counts) as ordered
  • Report any change in hearing or balance immediately
  • Avoid other potentially harmful drugs unless approved by your doctor
  • Stick to the prescribed dose and timing—never skip or double up

Balancing benefits and risks

Genglycos can be a lifesaver against tough infections. In most hospital protocols, its use is carefully managed:

  • Pharmacists calculate a weight-based dose
  • Blood levels may be monitored (peak and trough levels)
  • Therapy length is kept to the shortest effective duration

This approach helps you get the full antibacterial punch while keeping side effects in check.

What the experts say

According to prescribing information and reviews in reputable journals, the most common severe issue is kidney injury—seen in about 5–10% of cases without preventive measures. Ototoxicity rates vary but can be as high as 20% in older adults or patients with preexisting ear problems. Your care team will weigh these numbers against the severity of your infection.

When to consider further self-assessment

If you’re ever unsure whether a new symptom is drug-related, don’t guess. Try a free, online symptom check, using the doctor approved Ubie Symptom Checker for guidance on urgency and possible causes. It’s a quick way to get clarity before you call your doctor or head to the ER.

Key takeaways on genglycos side effects

  • Common side effects (kidney labs up, mild GI upset, injection-site soreness) are usually reversible.
  • Serious risks include nephrotoxicity, ototoxicity, neuromuscular blockade and severe allergic reactions.
  • High-risk groups need extra monitoring—stay ahead with scheduled labs and ear checks.
  • Hydration, avoiding other toxic drugs and close follow-up keep you safer.
  • Always report worrying symptoms right away—early action can prevent lasting harm.

No matter how experienced your medical team is, your input matters. If anything feels off, trust your instincts: do a symptom check, reach out to your provider, and never hesitate to seek help for potentially life-threatening reactions.

(References)

  • * Martínez-Carranza M, Blasco P, Gustafsson R, Dong M, Berntsson RP, Widmalm G, Stenmark P. Synaptotagmin Binding to Botulinum Neurotoxins. Biochemistry. 2020 Feb 4;59(4):491-498. doi: 10.1021/acs.biochem.9b00554. Epub 2019 Dec 18. PMID: 31809018.

  • * Moghimi B, Muthugounder S, Jambon S, Tibbetts R, Hung L, Bassiri H, Hogarty MD, Barrett DM, Shimada H, Asgharzadeh S. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nat Commun. 2021 Jan 21;12(1):511. doi: 10.1038/s41467-020-20785-x. Epub 2021 Jan 21. PMID: 33479234; PMCID: PMC7820416.

  • * Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, Richards RM, Jiang L, Barsan V, Mancusi R, Geraghty AC, Good Z, Mochizuki AY, Gillespie SM, Toland AMS, Mahdi J, Reschke A, Nie EH, Chau IJ, Rotiroti MC, Mount CW, Baggott C, Mavroukakis S, Egeler E, Moon J, Erickson C, Green S, Kunicki M, Fujimoto M, Ehlinger Z, Reynolds W, Kurra S, Warren KE, Prabhu S, Vogel H, Rasmussen L, Cornell TT, Partap S, Fisher PG, Campen CJ, Filbin MG, Grant G, Sahaf B, Davis KL, Feldman SA, Mackall CL, Monje M. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022 Mar;603(7903):934-941. doi: 10.1038/s41586-022-04489-4. Epub 2022 Feb 7. PMID: 35130560; PMCID: PMC8967714.

  • * Sgambati E, Tani A, Leri M, Delfino G, Zecchi-Orlandini S, Bucciantini M, Nosi D. Correlation between Sialylation Status and Cell Susceptibility to Amyloid Toxicity. Cells. 2022 Feb 9;11(4). doi: 10.3390/cells11040601. Epub 2022 Feb 9. PMID: 35203252; PMCID: PMC8870280.

  • * Zhang DY, Wang J, Fleeman RM, Kuhn MK, Swulius MT, Proctor EA, Dokholyan NV. Monosialotetrahexosylganglioside Promotes Early Aβ42 Oligomer Formation and Maintenance. ACS Chem Neurosci. 2022 Jul 6;13(13):1979-1991. doi: 10.1021/acschemneuro.2c00221. Epub 2022 Jun 17. PMID: 35713284; PMCID: PMC10137048.

  • * Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F, Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med. 2023 Apr 6;388(14):1284-1295. doi: 10.1056/NEJMoa2210859. PMID: 37018492.

  • * Ciccone R, Quintarelli C, Camera A, Pezzella M, Caruso S, Manni S, Ottaviani A, Guercio M, Del Bufalo F, Quadraccia MC, Orlando D, Di Cecca S, Sinibaldi M, Aurigemma M, Iaffaldano L, Sarcinelli A, D'Amore ML, Ceccarelli M, Nazio F, Marabitti V, Giorda E, Pezzullo M, De Stefanis C, Carai A, Rossi S, Alaggio R, Del Baldo G, Becilli M, Mastronuzzi A, De Angelis B, Locatelli F. GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma. Clin Cancer Res. 2024 Jun 3;30(11):2545-2557. doi: 10.1158/1078-0432.CCR-23-1880. PMID: 38551501; PMCID: PMC11145172.

  • * Lin FY, Stuckert A, Tat C, White M, Ruggieri L, Zhang H, Mehta B, Lapteva N, Mei Z, Major A, Thakkar S, Shum T, Parikh K, Wu MF, Lindsay HB, Scherer L, Shekar M, Baxter P, Wang T, Grilley B, Moeller K, Hicks J, Roy A, Anastas J, Malbari F, Aldave G, Chintagumpala M, Blaney S, Parsons DW, Brenner MK, Heslop HE, Rooney CM, Omer B. Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 Aug 10;42(23):2769-2779. doi: 10.1200/JCO.23.02019. Epub 2024 May 21. PMID: 38771986; PMCID: PMC11305939.

  • * Wei W, Fader ME, Kushner BH, Cardenas FI, Kramer K, Basu E, Modak S. Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma. Pediatr Blood Cancer. 2025 Sep;72(9):e31845. doi: 10.1002/pbc.31845. Epub 2025 Jun 23. PMID: 40551396; PMCID: PMC12558605.

  • * Rosenkrans ZT, Erbe AK, Clemons NB, Feils AS, Medina-Guevara Y, Jeffery JJ, Barnhart TE, Engle JW, Sondel PM, Hernandez R. ImmunoPET Demonstrates that Co-Targeting GD2 and B7-H3 with Bispecific Antibodies Enhances Tumor Selectivity in Preclinical Melanoma Models. Bioconjug Chem. 2025 Aug 20;36(8):1595-1603. doi: 10.1021/acs.bioconjchem.5c00016. Epub 2025 Jul 31. PMID: 40741919.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.